Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Proteasome Inhibitors Market Outlook

The global proteasome inhibitors market is expected to grow at a CAGR of 8.6% in the forecast period of 2024-2032 to reach nearly USD 3.77 billion by 2032.

Global Proteasome Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The industry is expanding due to the development in the research sector, providing treatment for multiple myeloma and drugs to treat pancreatic cancer. North America held the largest market share in 2018, however, it is anticipated to witness a slower growth during the forecast period because of the rising number of substitutes approved by the government, especially in the United States.

Market Segmentation

Proteasome inhibitors help in the prevention or delay in the degradation of proapoptotic factors. It facilitates the programmed cell death that ultimately cures the disease.

Global Proteasome Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The various product types of proteasome inhibitors are:

  • Velcade
  • Kyprolis
  • Ninlaro
  • Others

The EMR report looks into the regional proteasome inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Market Analysis

The global proteasome inhibitors market is being driven by the enormous unmet demand and expanding applications of proteasome inhibitors in the treatment of blood cancer and primarily myeloma. The industry is further aided by the rising prevalence of cancer, globally, as proteasome has proved to be efficient for treating cancer indications. The ability of the drug is prompting vendors to conduct studies on the therapeutics effects of the product on solid tumours, hence, promoting the growth of the industry. The other factor leading to the growth of the proteasome inhibitors market is the application of proteasome inhibitors in the treatment of various health conditions. North America accounted for the largest industry share in 2018 due to the high incidences of multiple myeloma and non-Hodgkin’s lymphoma in the region. However, Europe and Asia, are expected to witness a significant growth during the forecast period owing to increased incidences of myeloma and rising sales of proteasome inhibitors in the regions.

Global Proteasome Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

The report presents a detailed analysis of the following key players in the global proteasome inhibitors market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • AbbVie Inc.
  • Celgene Corp. (NASDAQ: CELG)
  • Johnson & Johnson Services Inc. (NYSE: JNJ)
  • The Takeda Pharmaceutical Company Limited
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Region
Breakup by Product
  • Velcade
  • Kyprolis
  • Ninlaro
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • AbbVie Inc.
  • Celgene Corporation
  • Johnson & Johnson Services Inc.
  • The Takeda Pharmaceutical Company Limited
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The global proteasome inhibitors market is projected to grow at a CAGR of 8.6% between 2023 and 2032.

The market is estimated to grow in the forecast period of 2024-2032 to reach about USD 3.77 billion by 2032.

The major drivers of the industry, such as the growing demand for proteasome inhibitors in the medical sector, growing incidences of cancer across the globe, increased government investment to develop the healthcare sector, and the growing technological advancements, are expected to aid the market growth.

The key market trends guiding the growth of the industry include the growing research and development activities and a rise in the number of clinical trials being conducted globally.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.

Velcade, kyprolis, and ninlaro, among others, are the leading proteasome inhibitors products in the industry.

The major players in the industry are AbbVie Inc., Celgene Corp. (NASDAQ: CELG), Johnson & Johnson Services Inc. (NYSE: JNJ), The Takeda Pharmaceutical Company Limited, Others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124